A Phase 1 interventional study of RGLS8429 and Placebo volume-matching RGLS8429 dose in Healthy Volunteers, sponsored by Regulus Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Regulus Therapeutics Inc. (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 38th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 10 in phase 1, and was the 66th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 19–55 · Men only · Healthy volunteers
Kenneth Hallows · Sites in United States
Ages 18–60
Mayo Clinic · Sites in United States
Ages 18–70
Richard Fatica · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, China, United Kingdom
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 18 · Phase 4 2
First in 1998; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 48 across the 63 interventional studies, 90 across the 22 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 85 have an industry lead sponsor. The 10 most frequent:
This study is registered under Regulus Therapeutics Inc., one of the names counted as Novartis. Under that name alone:
Regulus Therapeutics Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Novartis has 4 studies filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
16 of the studies in Polycystic Kidney, Autosomal Dominant with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05193981Mayo ClinicA Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | 2026-12 |
| NCT05288998Mayo ClinicIntrarenal Microvasculature in ADPKD | 2026-12 |
| NCT06786260Loma Linda UniversityDi-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease | 2026-12 |
| NCT04344769Mayo ClinicCharacterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2026-12 |
| NCT04630613Mayo ClinicNOX4 and Related Biomarkers in ADPKD | 2026-12 |
Add all 16 to your calendar (.ics) → With an account.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective
Secondary Objectives
In this randomized, double-blind, placebo-controlled Phase 1 study, a single ascending dose of RGLS8429 or placebo will be administered via subcutaneous (SC) injection to healthy volunteers to evaluate the safety, tolerability, and PK of RGLS8429.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive subcutaneous injection of the first dose level RGLS8429 or placebo
Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose
Eligible participants will receive subcutaneous injection of the second dose level RGLS8429 or placebo
Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose
Eligible participants will receive subcutaneous injection of the third dose level RGLS8429 or placebo
Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose
Eligible participants will receive subcutaneous injection of the fourth dose level RGLS8429 or placebo
Drug: RGLS8429 · Drug: Placebo volume-matching RGLS8429 dose
solution for subcutaneous injection
solution for subcutaneous injection
Incidence of Adverse Events (AEs)
Incidence and severity of adverse events after administration of RGLS8429
Time frame: Baseline to Day 29
Incidence of DLT and Determination of MTD
Identify dose limiting toxicity and the maximum tolerated dose after RGLS8429 administration
Time frame: Baseline to Day 29
Plasma Half-life (T1/2) of RGLS8429
Measure plasma elimination half-life after RGLS8429 administration
Time frame: Baseline to Day 15
Plasma Clearance of RGLS8429
Measure plasma clearance after RGLS8429 administration
Time frame: Baseline to Day 15
Area Under the Plasma Concentration vs Time Curve (AUC) of RGLS8429
Measure area under the plasma concentration vs time curve after RGLS8429 administration
Time frame: Baseline to Day 15
Amount of RGLS8429 Excreted in Urine
Measure the amount of RGLS8429 excreted in urine after RGLS8429 administration
Time frame: Baseline to 24-hour
| Milestone | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 8 |
| Completed | 6 | 6 | 6 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Incidence and severity of adverse events after administration of RGLS8429
| participants | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo |
|---|---|---|---|---|---|
| Number of subjects with Grade 3, 4 or 5 treatment-emergent adverse events | 0 | 0 | 0 | 0 | 0 |
| Number of subjects with Treatment-emergent adverse events leading to discontinuation | 0 | 0 | 0 | 0 | 0 |
| Number of Subjects with Serious Adverse Events or deaths | 0 | 0 | 0 | 0 | 0 |
| Number of subjects with at least one treatment-emergent adverse event | 1 | 1 | 3 | 1 | 3 |
Identify dose limiting toxicity and the maximum tolerated dose after RGLS8429 administration
Results for this outcome have not been posted.
Measure plasma elimination half-life after RGLS8429 administration
Results for this outcome have not been posted.
Measure plasma clearance after RGLS8429 administration
Results for this outcome have not been posted.
Measure area under the plasma concentration vs time curve after RGLS8429 administration
Results for this outcome have not been posted.
Measure the amount of RGLS8429 excreted in urine after RGLS8429 administration
Results for this outcome have not been posted.
Collected over All Adverse Events were collecting beginning with the start of study drug administration until the Day 29 End of Study Visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RGLS8429, First Dose Level | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| RGLS8429, Second Dose Level | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| RGLS8429, Third Dose Level | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| RGLS8429, Fourth Dose Level | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Matching Placebo | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 1/6 | 1/6 | 0/6 | 2/8 |
| Eustachian tube dysfunctionEar and labyrinth disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 |
| Medical device site reactionGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 |
| SinusitisInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Skin abrasionInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 |
| Dry mouthGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 |
| Age, Categorical(Participants) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 6 | 8 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 36.3 ± 9.48 | 33.8 ± 6.68 | 34.2 ± 6.18 | 38.2 ± 9.28 | 43.9 ± 6.58 | 37.7 ± 8.2 |
| Sex: Female, Male(Participants) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 5 | 2 | 8 | 20 |
| Male | 3 | 4 | 1 | 4 | 0 | 12 |
| Ethnicity (NIH/OMB)(Participants) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 5 | 2 | 7 | 24 |
| Not Hispanic or Latino | 0 | 2 | 1 | 4 | 1 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 | 0 | 1 | 5 |
| White | 6 | 4 | 4 | 5 | 7 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | RGLS8429, First Dose Level | RGLS8429, Second Dose Level | RGLS8429, Third Dose Level | RGLS8429, Fourth Dose Level | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 8 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Sep 2022, 2 months.
Results were first posted in Aug 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant →